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The use of polymerase chain reaction-single-stranded conformational poly-
morphism (PCR-SSCP) to study rpoB gene mutations in rifampin-resistant
(RIFr)  Mycobacterium tuberculosis has yielded contradictory results. To
determine the sensitivity of this method, we analyzed 35 RIFr strains and 11
rifampin-susceptible (RIFs) strains, using the DNA sequencing of the core
region of rpoB for comparison. Of the RIFr, 24 had a PCR-SSCP pattern
identical to that of H37Rv; the other 11 had four different patterns. The 11
RIFs had PCR-SSCP patterns identical to that of H37Rv. The sensitivity of
the assay was 31.4%; its specificity was 100%. We observed a strong cor-
relation between the degree of resistance and the type of mutation. 
In the developed world, tuberculosis (TB), once consid-
ered to have been essentially eliminated, has rebounded and
is increasingly caused by drug-resistant strains. In develop-
ing countries, however, TB has been an unrelenting scourge.
Increasing international travel and migration contribute to
its widespread dissemination. Consequently, in 1993, the
World Health Organization declared TB to be a global emer-
gency (1).
Drug-resistant TB is a widespread phenomenon, with
primary isoniazid-resistance rates as high as 32% and pri-
mary multidrug resistance close to 15% in the former Soviet
Union. In Latin America, primary resistance to isoniazid
varies from 1% in Uruguay to 20% in the Dominican Repub-
lic, and primary multidrug resistance is as high as 7% in the
Dominican Republic and 5% in Argentina (2). In 1995, we
reported increasing resistance rates to isoniazid and
rifampin, four times higher than previously reported rates
for Mexico (3). Since then, several studies have addressed
this issue in different settings: urban, semi-urban, and rural
areas. The common finding has been a high rate of primary
resistance to isoniazid and to the combination of isoniazid
and rifampin (4,5). In 2000, a collaborative effort between
the Centers for Disease Control and Prevention and the
Mexican TB control program reported an 11% rate of pri-
mary isoniazid resistance and 2% of primary multidrug
resistance (6).
From the public health perspective, the impact of resis-
tance on disease and death has recently been emphasized (7)
in settings where HIV is highly prevalent. However, its
impact is also high in semi-urban settings without the influ-
ence of HIV infection (8). Thus, reliable methods are
urgently needed to rapidly detect resistance, particularly to
rifampin (a marker for multidrug resistance), without cum-
bersome traditional methods or use of radioactivity (9).
Several techniques use polymerase chain reaction
(PCR)-based strategies to rapidly detect mutations known to
confer resistance. One such method is single-stranded con-
formational polymorphism (SSCP) analysis, which involves
amplification by PCR of a segment of the gene encoding for
the specific drug target and comparison of PCR products of
drug-sensitive and drug- resistant strains by SSCP, in which
mutations usually result in an altered pattern (9,10). This
technique is relatively simple and was promising initially,
but recent studies have questioned its sensitivity and speci-
ficity (10). We investigated the usefulness of PCR-SSCP to
detect mutations in the rpoB gene of Mycobacterium tubercu-
losis strains with a wide range of rifampin resistance and
whether specific mutations in this gene are associated with
degree of rifampin resistance.
Methods
Clinical Isolates
Forty-six clinical isolates of  M. tuberculosis were
included in this study; all isolates were recovered from spu-
tum samples of patients from Mexico City and were fully
characterized by conventional methods (11). All strains were
resistant to at least one primary antituberculosis agent (iso-
niazid 0.1 µg/mL, rifampin 2 µg/mL, streptomycin 6 µg/mL,
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or ethambutol 7.5 µg/mL). Thirty-five strains were rifampin
resistant (RIFr), and 11 were rifampin sensitive (RIFs).
MICs to the primary antituberculosis drugs were deter-
mined by the radiometric method (Becton Dickinson, Cock-
eysville, MD) (12). 
PCR Amplification
Chromosomal DNA was extracted by conventional
methods (13). A 157-bp fragment of the  rpoB gene was
amplified by PCR with primers Tb8 (5'TGCACGTCGCGG
ACCTCCA3') and Tb9 (5'TCGCCGCGATCAAGGAGT3').
PCR was carried out in 50 µL of a reaction mixture contain-
ing 50 mM KCl, 10 mM Tris (pH 8.0), 1.5 mM MgCl2, 100 µM
of deoxynucleoside triphosphates (dNTPs), 1U  Taq  poly-
merase, 10 pmoles of each set of primers, and 10 ng of chro-
mosomal DNA. Samples were then subjected to one cycle at
94°C for 5 min, followed by 40 cycles at 94°C for 1 min, 55°C
for 1 min, 72°C for 1 min, and a final cycle at 72°C for 8 min
to complete the elongation of the PCR intermediate products.
PCR products were then run on 2% agarose gels and exam-
ined for the presence of the 157-bp band after ethidium bro-
mide staining.
Screening of SSCP-PCR Products
The SSCP of PCR products was analyzed by electro-
phoresis with 12% acrylamide gels. In brief, 25 µL of the
amplified product was diluted with 100 µL of buffer (0.1%
sodium dodecyl sulfate, EDTA 10 mM); 3 µL of this dilution
was mixed with 3 µL of loading buffer (95% formamide, 20
mM EDTA, and 0.05% each of bromophenol blue and xylene
cyanol). The mixtures were boiled for 2 min, cooled in ice for
5 min, and then loaded on the gel at 40V for 10 h at room
temperature. The gels were silver stained and allowed to
dry. The drug-susceptible strain H37Rv was run side by side
with the clinical isolates as a control for all experiments.
Three different PCR products were analyzed five times each.
DNA Sequencing
A 411-bp fragment of the  rpoB gene, containing the
sequence of the 157-bp  rpoB fragment, was amplified by
PCR using primers TR1 (5' TACGGTCGGCGAGCT
GATCC3') and TR2 (5'TACGGCGTTTCGATGAACC3'). PCR
was carried out in 25 µL containing 50 mM KCl, 10 mM Tris
(pH 8.0), 0.7 mM MgCl2, 100 µM dNTPs, 1U  Taq poly-
merase, and 10 ng of DNA template. Samples were then sub-
jected to one cycle at 94°C for 5 min, followed by 40 cycles at
94°C for 1 min, 55°C for 1 min, 72°C for 1 min, and a final
cycle at 72°C for 8 min to complete the elongation of the PCR
intermediate products. These products were characterized
by electrophoresis on 2% agarose gels and stained in 0.5 µg/
mL of ethidium bromide.
PCR products were sequenced directly on an Applied
Biosystems 373A automated DNA sequencer (Perkin Elmer,
Foster City, CA). Samples that gave a single band on agarose
gels were purified (Wizard PCR Preps, Promega, Madison,
WI) to remove excess primers and nucleotides. Sequencing
was done with a PRISM dye terminator cycle sequencing kit
(Perkin Elmer), following the manufacturer’s instructions. 
Statistical Analysis
Sensitivity and specificity of the PCR-SSCP method
were determined by using the test for 2X2 contingency
tables. Differences in the mean MIC logs among strains with
specific mutations were calculated by the two-sample Wil-
coxon rank-sum test (Mann-Whitney U test).
Results
Rifr Pattern among M. tuberculosis Isolates
The 35 RIFr isolates had MIC values as follows: two iso-
lates had an MIC of 2 µg/mL; six of 8 µg/mL; one of 16 µg/
mL; one 32 µg/mL; two of 64 µg/mL; two of 128 µg/mL; eight
of 256 µg/mL; one of 512 µg/mL; two of 1,024 µg/mL, and ten
of 2,048 µg/mL. All 11 rifampin-susceptible isolates had MIC
values <0.5 µg/mL, but all of them were resistant to at least
one other primary antituberculosis agent.
SSCP Analysis
SSCP assays were repeated at least five times with
three different amplicons for all isolates with 100% repro-
ducibility. On the basis of the SSCP results, the 35 RIFr iso-
lates were grouped in two main categories: group one, 24
isolates (68.6%) with an SSCP identical to that of the control
strain H37Rv, and group two, 11 isolates (31.4%) with an
SSCP different from that of H37Rv. The MICs were variable
in group one. In group two, four polymorphisms were
observed with different MICs (Figure). The 11 RIFs isolates
showed an SSCP identical to that of H37Rv. Therefore, the
overall sensitivity of the assay was 31.4%, with a specificity
of 100%. It was not possible to correlate the MIC values with
the polymorphisms because each strain had a different MIC.
DNA-Sequencing Analysis
No mutations were found in the core region of the rpoB
gene in the 11 RIFs isolates. All 35 RIFr isolates showed a
mutation by sequence analysis. Seven different missense
mutations were observed, with all but one detected within
the core region. These mutations produced 13 changes in
amino acid content (Table). Mutations at specific codons
were associated with the level of resistance; significantly
higher MICs were observed when point mutations occurred
in codon 513 (median MIC 2,048 µg/mL; p=0.001), in codon
526 (median MIC 2048 µg/mL, p=0.002), and in codon 531
(median MIC 256 µg/mL, p=0.002), compared with muta-
tions at codon 516 (median MIC 8 µg/mL). Single strains
Figure. Representative polymerase chain reaction single-stranded conforma-
tional polymorphism (SSCP) patterns of rifampin resistance in Mycobacterium
tuberculosis strains. Lanes: 1, 18, molecular weight FC174/HaeIII; lanes: 2,
17, M. tuberculosis rifampin-susceptible control strain H37Rv; lanes 3, 4, 5
(MICs 2,8,64 µg/mL), pattern 1 rifampin-resistant strains with a pattern indis-
tinguishable from that of M. tuberculosis H37Rv; lanes 6,7,8 (MICs 2, 8, 2,048
µg/mL), pattern 2a; lanes 9,10,11 (MICs 2048, 256, 256 µg/mL), pattern 2b;
lanes 12,13,14,15 (MICs 2048, 2048, 256, 1,024 µg/mL), pattern 2c; lane 16
(MIC 128 µg/mL), pattern 2d.Research
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with low-level resistance had mutations at codons 522 (MIC
8 µg/mL), 533 (MIC 2 µg/mL), and 572 (MIC 2 µg/mL)
(Table). Three mutations in codon 531 had not been
described previously. Neither insertions nor deletions were
detected in this group of strains.
Discussion
PCR-SSCP has been used extensively to search for
genetic diseases (14,15) and recently to detect missense
mutations associated with antibiotic resistance in M. tuber-
culosis (9,10,16,17). In spite of extensive and comprehensive
standardization of the PCR-SSCP method, our data show
that this procedure was highly specific but had poor sensitiv-
ity for detecting mutations in the  rpoB gene in rifampin-
resistant clinical isolates of M. tuberculosis, since two thirds
of the resistant isolates had a PCR-SSCP pattern similar to
that of the M. tuberculosis susceptible control strain H37Rv.
Our results differ from those of the investigators who
first tested this technique to detect rifampin resistance in
M. tuberculosis and demonstrated a clear association
between rpoB mutations and the resistance profile (9). How-
ever, in recent studies, this method has detected silent and
missense mutations in susceptible strains (18). We did not
find these types of mutations, but we did find 24/35 (68.6%)
false-negative results. Furthermore, in a recent study by Lee
et al. in Korea, false-negative results were obtained in 17
(25.4%) of 67 strains (10). Although suboptimal technical
conditions may account for the poor PCR-SSCP performance,
missense mutations were found after nucleotide sequencing
in rifampin-resistant strains.
Although the method was fully reproducible, after the
data were controlled for all variables, our data also indicate
that this method may perform poorly in detecting mutations
in this region. To confirm our findings with PCR-SSCP, we
determined the nucleotide sequence in 35 rifampin-resistant
M. tuberculosis strains and observed missense mutations in
all of them (Table).
After sequence analysis, all the highly rifampin-resis-
tant (>128 µg/mL) isolates were found to have point muta-
tions in codons 513, 526, and 531, which were the most
common in our study population, corroborating that these
mutations are the most prevalent worldwide (19). Since our
strains showed different types of mutations, we do not
endorse the recently suggested idea of a geographic distribu-
tion of single mutations (20,21). Additionally, we observed
three alleles in codon 531 that had not been described previ-
ously: two strains showed an TCG/GCG (Ser/Ala) exchange,
one an TCG/CCG (Ser/Pro) exchange, and another an TCG/
TTC (Ser/Phe) exchange.
There was a strong correlation between the degree of
resistance and any nucleotide substitution in specific codons.
Mutations associated with nucleotide replacements in
codons 513, 526, and 531 were associated with high-level
rifampin resistance, whereas mutations in codon 516 were
observed in low-level rifampin resistance (p<0.005) (Table).
Other authors have reported high (22,23) and low (24) levels
of resistance associated with specific nucleotide replace-
ments. These differences reflect the complex and crucial
interaction between the drug and its target at the molecular
level, where the position of the affected allele seems to be
critical.
An additional interesting finding was that one strain
with an MIC of 2 µg/mL did not show a mutation within the
81-bp core region, although a missense mutation ATC/TTC
(Ile/Phe) was seen in codon 572, which may explain the
rifampin resistance detected in this strain. This observation
confirms a recent report of a rifampin-resistant strain identi-
fied in Australia with an identical mutation outside the core
region of rpoB (25).
Although the SSCP method performed poorly in our set-
ting, other DNA sequence-based approaches to detecting
rifampin resistance may still have merit, since the vast
majority of mutations occur in precisely defined positions.
For example, INNO-LIPA (26) is a promising method based
on specific detection of previously identified resistance-con-
ferring mutations. Alternatively, other methods based on
cell viability, such as use of mycobacteriophages and
reporter genes, have shown promise (27, 28).
In conclusion, the practical implications of our study are
that the PCR-SSCP method may not be a reliable tool for the
detection of resistance to rifampin in M. tuberculosis. However,
Table. Mutations of the  rpoB gene found in 35 rifampin-resistant
Mycobacterium tuberculosis isolates 
Mutated
rpoB 
codon
Specific
Mutation
Strain
n
MIC 
(µg/mL) pc
513 CAA/AAA(Gln/Lys) 1 2,048 0.01
CAA/AAA(Gln/Lys) 1 256 0.01
CAA/CCA(Gln/Pro) 1 2,048 0.01
516 GAC/GTC(Asp/Val) 5 37,118 0.01, 0.002
526 CAC/TAC(His/Tyr) 1 256 0.01, 0.002
CAC/TAC(His/Tyr) 1 1,024 0.01, 0.002
CAC/TAC(His/Tyr) 3 2,048 0.01, 0.002
CAC/GAC(His/Asp) 2 256 0.01, 0.002
CAC/GAC(His/Asp) 1 128 0.01, 0.002
CAC/GAC(His/Asp) 1 2,048 0.01, 0.002
531 TCG/TTG(Ser/Leu) 1 32 0.002
TCG/TTG(Ser/Leu) 1 64 0.002
TCG/TTG(Ser/Leu) 4 256 0.002
TCG/TTG(Ser/Leu) 1 1,024 0.002
TCG/TTG(Ser/Leu) 3 2,048 0.002
TCG/CCG(Ser/Pro)b 1 8 0.002
TCG/GCG(Ser/Ala)b 1 64 0.002
TCG/GCG(Ser/Ala)b 1 128 0.002
TCG/TGG(Ser/Trp) 1 512 0.002
TCG/TTC (Ser/Phe)b 1 2,048 0.002
522 TCG/TTG (Ser/Leu) 1 8
533 CTG/CCG (Leu/Pro) 1 2
572 ATC/TTC (Ile/Phe)a 1 2
aThis mutation is located outside the core region.
bNot previously described.
cMann-Whitney test.Research
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if our observation of a strong correlation between specific muta-
tions and the level of resistance is confirmed in other settings,
the level of rifampin resistance may be predictable by DNA
sequence-based resistance detection methods.
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